Clinical Trials
18 trialsNCT04911907 2026-04-03
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Completed
NCT04891198 2026-03-25
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
3D Medicines
Phase 2 Recruiting
NCT04617054 2026-01-21
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
Nuvation Bio Inc.
Phase 2 Terminated
NCT07003321 2025-12-18
A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
NCT05119907 2025-11-17
Study of Sacituzumab Govitecan in Patients With Solid Tumor
Gilead Sciences
Phase 2 Active not recruiting
NCT05642780 2025-10-14
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Klus Pharma Inc.
Phase 2 Active not recruiting
NCT04827576 2025-05-08
ELEVATELung&UC
Gilead Sciences
Phase 2 Terminated
NCT06117540 2024-11-19
A Study of WX390 in Patients With Advanced Solid Tumors
Shanghai Jiatan Pharmatech Co., Ltd
Phase 2 Recruiting
NCT03861156 2024-04-09
D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
InventisBio Co., Ltd
Phase 2 Completed
NCT03834220 2024-02-07
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
Debiopharm International SA
Phase 2 Terminated
NCT04346381 2023-09-18
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT05284214 2023-09-15
SALIENT
Partner Therapeutics, Inc.
Phase 2 Withdrawn
NCT05898451 2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2 Completed
NCT05528406 2022-09-06
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation
Shanghai Henlius Biotech
Phase 2 Unknown
NCT03865082 2022-02-17
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Idera Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT04180384 2021-07-29
A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients
Athenex, Inc.
Phase 2 Completed
NCT03147976 2019-08-28
QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors
NantPharma, LLC
Phase 2 Withdrawn
NCT00982657 2015-11-20
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Pfizer
Phase 2 Terminated